PLS A.I CyberSecurity Scoring
12/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for PPD™ Laboratory Services in 2026.
No incidents recorded for PPD™ Laboratory Services in 2026.
No incidents recorded for PPD™ Laboratory Services in 2026.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
Latest updates, reports, and threat intel affecting the global network.
Evidera will become a wholly owned subsidiary of PPD, delivering peri- and post-approval studies, health economics, outcomes research, epidemiology and market...
A remote attacker who controls a container registry may be able to direct a client's token request to a host of the attacker's choice, and disclose the victim's registry credentials to that host. This vulnerability is addressed in containerization version 0.41.0.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the djust live transport resolves the LiveView to mount from a client-supplied dotted path by calling `__import__(module_path, ...)`. The module is imported — running its top-level code (import side effects) — before the framework checks that the resolved object is a `LiveView` subclass and before any per-view authentication. The `LIVEVIEW_ALLOWED_MODULES` allowlist that should contain this is fail-open (`if allowed_modules:` — skipped when the setting is unset, the framework default) and uses loose `startswith` matching. An unauthenticated WebSocket client (the WS handshake does not require auth; per-view auth runs only after import + instantiate) can therefore send a `mount` / `live_redirect_mount` / `url_change` frame (or an SSE mount) with `view = "<any.importable.module>.AnyName"` and cause the server to import — and execute the top-level code of — any importable Python module by name. Version 1.0.7 fixes the issue with a fail-closed resolution gate (`djust._view_resolution.is_view_import_allowed`): a client view path resolves only if (a) its module is already loaded (`sys.modules` — so resolving runs no new code; URL-routed views loaded by URLconf at startup keep working with zero config) or (b) it matches `LIVEVIEW_ALLOWED_MODULES` on a module-segment boundary (explicit opt-in for lazily-imported views). The gate runs before `__import__` at all three sinks (+ defense-in-depth inside `_instantiate_view`). As a workaround, set `LIVEVIEW_ALLOWED_MODULES` to the narrow list of modules that contain your mountable LiveView classes. (Note: pre-patch the allowlist is `startswith`-matched and the import still precedes the subclass check, so this is mitigation, not a complete fix.)
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, djust's per-object authorization (`get_object` + `has_object_permission`, ADR-017) was enforced on the WebSocket mount and event paths but not on three other render entry points: (a) the initial HTTP GET render, (b) SPA `url_change` navigation, and (c) `{% live_render %}` embedded child views. An authenticated user could therefore view (and on some paths act on) an object they are not authorized for by loading the page directly, navigating to it via SPA url-change, or composing it as an embedded child — a classic IDOR / broken object-level access control on object-scoped views. This is fixed in djust 1.0.7. All render entry points now route through a shared `enforce_object_permission` chokepoint: HTTP GET returns 403, `url_change` emits a `permission_denied` frame and skips the render, and `{% live_render %}` (eager + lazy) refuses the embed. Views without a custom `get_object` are unaffected (no-op). No reliable workaround short of upgrading. Do not expose object-scoped views through the HTTP-GET / url_change / live_render paths until patched.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the WebSocket `handle_mount` and `ViewRuntime._build_request` rebuild an `HttpRequest` via `RequestFactory().get(...)` with no `HTTP_HOST`, so `request.get_host()` defaulted to `"testserver"` on the live path. Host/subdomain/domain `TenantResolver`s then misresolved the tenant — `None` on the live path while the HTTP path resolved correctly. With `STRICT_MODE=False` the tenant-scoped managers returned unscoped rows (cross-tenant disclosure); with the default they returned an empty queryset (broken tenancy). This is fixed in djust 1.0.7. The handshake Host is extracted from the ASGI scope, validated against `ALLOWED_HOSTS` (the same logic as the CSWSH Origin gate, parsed with Django's `split_domain_port` so malformed Hosts are rejected at the boundary), and propagated — with the TLS scheme — into the reconstructed request, so live-path tenant resolution matches HTTP exactly. There is no known workaround on the live path short of upgrading. Users are most exposed when combined with `STRICT_MODE=False`.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, when a Django `Model` instance is assigned to a public view attribute, djust serialized it to the client with no sensitive-field denylist — sending fields such as `password` (the hash), privilege flags (e.g. `is_staff` / `is_superuser`), tokens, and other PII to the browser. Because exposing model objects to templates is a normal djust pattern, this could leak credentials/PII without the developer realizing the full object crossed the wire. This is fixed in djust 1.0.7. Model serialization applies a secure-by-default sensitive-field denylist (password/hash/token/secret-style fields and known privilege flags are withheld) with an identity-subset fallback. As a workaround, keep `Model` instances on `_private` attributes and expose only the specific fields needed, until patched.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.